Tidal Investments LLC lessened its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 20.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 83,492 shares of the company’s stock after selling 20,986 shares during the period. Tidal Investments LLC’s holdings in Cellebrite DI were worth $1,839,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also modified their holdings of CLBT. Raymond James Financial Inc. acquired a new position in Cellebrite DI during the 4th quarter worth about $9,995,000. Teacher Retirement System of Texas acquired a new position in Cellebrite DI during the 4th quarter worth about $442,000. New York State Common Retirement Fund lifted its stake in Cellebrite DI by 2.6% during the 4th quarter. New York State Common Retirement Fund now owns 189,599 shares of the company’s stock worth $4,177,000 after acquiring an additional 4,838 shares in the last quarter. SG Americas Securities LLC lifted its stake in Cellebrite DI by 2,244.2% during the 4th quarter. SG Americas Securities LLC now owns 209,529 shares of the company’s stock worth $4,616,000 after acquiring an additional 200,591 shares in the last quarter. Finally, Pembroke Management LTD lifted its stake in Cellebrite DI by 4.4% during the 4th quarter. Pembroke Management LTD now owns 1,992,432 shares of the company’s stock worth $43,893,000 after acquiring an additional 84,087 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on CLBT shares. Lake Street Capital increased their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. JPMorgan Chase & Co. decreased their target price on Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday, May 12th. Finally, Needham & Company LLC reduced their price target on Cellebrite DI from $28.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $22.43.
Cellebrite DI Price Performance
CLBT stock opened at $17.21 on Friday. The firm has a market capitalization of $4.12 billion, a P/E ratio of -12.38, a P/E/G ratio of 4.27 and a beta of 1.44. The business’s 50-day moving average is $18.91 and its two-hundred day moving average is $20.18. Cellebrite DI Ltd. has a 1 year low of $10.25 and a 1 year high of $26.30.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. The company had revenue of $107.55 million for the quarter, compared to analyst estimates of $109.36 million. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Cellebrite DI’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 EPS. On average, analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.
Cellebrite DI Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
- Five stocks we like better than Cellebrite DI
- Canadian Penny Stocks: Can They Make You Rich?
- Pfizer’s 7.5% Dividend: Income Haven or House of Cards?
- 3 REITs to Buy and Hold for the Long Term
- 3 Trades Members of Congress Are Making Right Now
- What is the Dogs of the Dow Strategy? Overview and Examples
- TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.